Cargando…
Novel Modification of a Confirmatory SMA Sequencing Assay that Can Be Used to Determine SMN2 Copy Number
Promising treatments for spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, prompted calls for inclusion in newborn screening (NBS). In January 2018, the New England Newborn Screening Program (NENSP) began statewide screening for SMA using a tiered algorithm looking for th...
Autores principales: | Kumar, Binod, Barton, Samantha, Kordowska, Jolanta, Eaton, Roger B., Counihan, Anne M., Hale, Jaime E., Comeau, Anne Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395917/ https://www.ncbi.nlm.nih.gov/pubmed/34449530 http://dx.doi.org/10.3390/ijns7030047 |
Ejemplares similares
-
A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients
por: Savad, Shahram, et al.
Publicado: (2023) -
Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
por: Crawford, Thomas O., et al.
Publicado: (2012) -
Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients
por: Blasco‐Pérez, Laura, et al.
Publicado: (2021) -
Functional characterization of SMN evolution in mouse models of SMA
por: Osman, Erkan Y., et al.
Publicado: (2019) -
The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)